• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期I期高级别浆液性卵巢癌的免疫逃逸机制:调节性T细胞动态变化的见解

Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics.

作者信息

Mikulak Joanna, Terzoli Sara, Marzano Paolo, Cazzetta Valentina, Martiniello Giampaolo, Piazza Rocco, Viano Maria Estefania, Vitobello Domenico, Portuesi Rosalba, Grizzi Fabio, Hegazi Mohamed A A A, Fiamengo Barbara, Basso Gianluca, Parachini Lara, Mannarino Laura, D'Incalci Maurizio, Marchini Sergio, Mavilio Domenico

机构信息

Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

出版信息

Cell Death Dis. 2025 Apr 1;16(1):229. doi: 10.1038/s41419-025-07557-5.

DOI:10.1038/s41419-025-07557-5
PMID:40164596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11958665/
Abstract

The mechanisms driving immune evasion in early-stage I high-grade serous ovarian carcinoma (HGSOC) remain poorly understood. To investigate this, we performed single-cell RNA-sequencing analysis. Our findings revealed a highly immunosuppressive HGSOC microenvironment, characterized by abundant infiltration of regulatory T cells (Tregs). Trajectory analysis uncovered differentiation pathways of naïve Tregs, which underwent either activation and proliferation or transcriptional instability. The predicted Treg-cell interaction network, including crosstalk within tumor cells, facilitates Treg mobility and maturation while reinforcing their immunosuppressive function and persistence in the tumor. Moreover, their interactions with immune cells likely inhibit CD8 T cells and antigen-presenting cells, supporting tumor immune escape. Additionally, more immunogenic tumor conditions, marked by IFNγ production, may contribute to Treg destabilization. Our findings underscore the pivotal role of Tregs in early immune evasion of HGSOC and provide insights into potential therapeutic strategies targeting their activity and differentiation fate.

摘要

早期I期高级别浆液性卵巢癌(HGSOC)中驱动免疫逃逸的机制仍知之甚少。为了对此进行研究,我们进行了单细胞RNA测序分析。我们的研究结果揭示了一种高度免疫抑制的HGSOC微环境,其特征是调节性T细胞(Tregs)大量浸润。轨迹分析揭示了幼稚Tregs的分化途径,其经历了激活和增殖或转录不稳定性。预测的Treg细胞相互作用网络,包括肿瘤细胞内的串扰,促进了Tregs的迁移和成熟,同时增强了它们在肿瘤中的免疫抑制功能和持久性。此外,它们与免疫细胞的相互作用可能会抑制CD8 T细胞和抗原呈递细胞,支持肿瘤免疫逃逸。此外,以产生IFNγ为特征的更多免疫原性肿瘤状态可能导致Treg不稳定。我们的研究结果强调了Tregs在HGSOC早期免疫逃逸中的关键作用,并为针对其活性和分化命运的潜在治疗策略提供了见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/c56ee233e68c/41419_2025_7557_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/d767ca0c0481/41419_2025_7557_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/658ff829c6bc/41419_2025_7557_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/e441a4774cd5/41419_2025_7557_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/03c45d108e17/41419_2025_7557_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/0a1f073062a8/41419_2025_7557_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/58ac1177bd3f/41419_2025_7557_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/c56ee233e68c/41419_2025_7557_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/d767ca0c0481/41419_2025_7557_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/658ff829c6bc/41419_2025_7557_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/e441a4774cd5/41419_2025_7557_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/03c45d108e17/41419_2025_7557_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/0a1f073062a8/41419_2025_7557_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/58ac1177bd3f/41419_2025_7557_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0c/11958665/c56ee233e68c/41419_2025_7557_Fig7_HTML.jpg

相似文献

1
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics.早期I期高级别浆液性卵巢癌的免疫逃逸机制:调节性T细胞动态变化的见解
Cell Death Dis. 2025 Apr 1;16(1):229. doi: 10.1038/s41419-025-07557-5.
2
Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies.通过单细胞RNA测序表征高级别浆液性卵巢癌的肿瘤生物学和免疫微环境:对靶向和个性化免疫治疗策略的见解
Front Immunol. 2025 Jan 17;15:1500153. doi: 10.3389/fimmu.2024.1500153. eCollection 2024.
3
Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.基因共表达网络和免疫细胞图谱的亚型特异性分析揭示了高级别浆液性卵巢癌亚型与可变免疫微环境的联系。
J Ovarian Res. 2024 Dec 3;17(1):240. doi: 10.1186/s13048-024-01556-4.
4
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.高级别浆液性卵巢癌的综合免疫基因组分析揭示了联合免疫疗法的潜在敏感性。
Front Immunol. 2024 Nov 28;15:1489235. doi: 10.3389/fimmu.2024.1489235. eCollection 2024.
5
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.CD8+T 细胞与 CD4+CD25+FOXP3+和 FOXP3-T 细胞的比值与人类浆液性卵巢癌的不良临床结局相关。
PLoS One. 2013 Nov 14;8(11):e80063. doi: 10.1371/journal.pone.0080063. eCollection 2013.
6
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.人类高级别浆液性卵巢癌肿瘤微环境的复杂网络。
Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.
7
Ovarian cancer mutational processes drive site-specific immune evasion.卵巢癌突变过程驱动特定部位的免疫逃逸。
Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14.
8
Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer.安罗替尼与免疫疗法联合应用可增强高级别浆液性卵巢癌的抗血管生成和免疫反应。
Front Immunol. 2025 Apr 7;16:1539616. doi: 10.3389/fimmu.2025.1539616. eCollection 2025.
9
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.靶向间皮素-CD24轴可使肿瘤相关巨噬细胞重新极化,以增强高级别浆液性卵巢癌的PD-1阻断治疗效果。
J Immunother Cancer. 2025 Feb 25;13(2):e011230. doi: 10.1136/jitc-2024-011230.
10
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.载脂蛋白B mRNA编辑酶催化多肽样3G(APOBEC3G)的表达与高级别浆液性卵巢癌中的T细胞浸润及改善的临床预后相关。
Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910. Epub 2016 Mar 25.

引用本文的文献

1
Impact of sympathetic nervous system on immune evasion in high-grade serous ovarian cancer: a review.交感神经系统对高级别浆液性卵巢癌免疫逃逸的影响:综述
Front Oncol. 2025 Aug 8;15:1644895. doi: 10.3389/fonc.2025.1644895. eCollection 2025.
2
Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.乳腺癌和女性生殖道癌中的肿瘤浸润淋巴细胞:被忽视的潜力与未被探索的前沿领域。
Cancer Med. 2025 Jul;14(13):e71023. doi: 10.1002/cam4.71023.

本文引用的文献

1
Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer.绘制卵巢癌中空间组织和遗传细胞状态调控因子图谱以靶向免疫逃逸。
Nat Immunol. 2024 Oct;25(10):1943-1958. doi: 10.1038/s41590-024-01943-5. Epub 2024 Aug 23.
2
Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers.研究原发性卵巢癌中增殖细胞的空间分布。
Discov Med. 2024 Mar;36(182):632-645. doi: 10.24976/Discov.Med.202436182.60.
3
Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.
从单细胞RNA测序数据预测肿瘤反应性T细胞受体用于个性化T细胞治疗。
Nat Biotechnol. 2025 Jan;43(1):134-142. doi: 10.1038/s41587-024-02161-y. Epub 2024 Mar 7.
4
IL-23 stabilizes an effector T cell program in the tumor microenvironment.IL-23 在肿瘤微环境中稳定效应 T 细胞程序。
Nat Immunol. 2024 Mar;25(3):512-524. doi: 10.1038/s41590-024-01755-7. Epub 2024 Feb 14.
5
Targeting the immune microenvironment for ovarian cancer therapy.针对卵巢癌治疗的免疫微环境。
Front Immunol. 2023 Dec 18;14:1328651. doi: 10.3389/fimmu.2023.1328651. eCollection 2023.
6
CD4CCR8 Tregs in ovarian cancer: a potential effector Tregs for immune regulation.CD4CCR8+Tregs 在卵巢癌中的作用:一种潜在的效应性 Tregs,可用于免疫调节。
J Transl Med. 2023 Nov 10;21(1):803. doi: 10.1186/s12967-023-04686-3.
7
Modulating Treg stability to improve cancer immunotherapy.调节调节性T细胞稳定性以改善癌症免疫疗法。
Trends Cancer. 2023 Nov;9(11):911-927. doi: 10.1016/j.trecan.2023.07.015. Epub 2023 Aug 17.
8
Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.卵巢癌患者腹水中具有抗肿瘤特性的组织驻留自然杀伤细胞和T淋巴细胞的鉴定
Cancers (Basel). 2023 Jun 27;15(13):3362. doi: 10.3390/cancers15133362.
9
Ovarian cancer mutational processes drive site-specific immune evasion.卵巢癌突变过程驱动特定部位的免疫逃逸。
Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14.
10
Regulatory T-cell stability and functional plasticity in health and disease.健康与疾病状态下调节性T细胞的稳定性及功能可塑性
Immunol Cell Biol. 2023 Feb;101(2):112-129. doi: 10.1111/imcb.12613. Epub 2022 Dec 26.